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Introduction: Little is known if hemostatic markers and serum lipid fractions can predict
further radiological progression beyond vascular risk factors in cerebral small vessel disease
(SVD). We investigated whether they are associated with SVD radiological progression and if
they are related to different SVD clinical manifestations.
Methods: A single-center, prospective, cohort study with 2 years of radiological follow-up
was performed in consecutive patients with different SVD manifestations. The study group
consisted of 123 patients: 49 with lacunar stroke (LS), 48 with vascular dementia (VaD) and 26
with vascular parkinsonism (VaP). We assessed SVD progression by a visual SVD scale. We
determined the relationship between serum or plasma concentrations of tissue factor (TF),
thrombomodulin, beta-thromboglobulin (BTG), ﬁbrinogen, D-dimer and total cholesterol,
HDL-C, LDL-C, triglycerides and SVD progression by logistic regression analysis.
Results: 34.9% patients had SVD radiological progression: 43% had isolated WMLs progres-
sion, 23.2% had new lacunes, 34.8% had both WMLs progression and new lacunes. Fibrinogen
[OR 1.02 (95% CI 1.006–1.011] was signiﬁcantly associated with risk of new lacunes or WMLs
progression regardless of the clinical SVD manifestation. While low HDL [OR 0.96 (0.93–1)]
and TF [OR 1.07 (0.99–1.1)] were marginally associated with new lacunes, BTG [OR 1.005 (0.99–
1.01)] was associated with WMLs progression.
Conclusion: We found a relationship between ﬁbrinogen and risk of radiological progression
of SVD regardless of the clinical SVD manifestation. In addition, lower HDL and increased TF
predicted development of new lacunes, and higher BTG was associated with risk of WMLs
progression.
© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
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Cerebral small vessel disease (SVD) is one of the most
important and common vascular diseases of the brain caused
by lacunar infarcts (LI) and white matter lesions (WMLs). It
refers to different but pathogenetically linked processes and
mechanisms: atherosclerosis, arteriolosclerosis, lipohyalino-
sis but also it results from increased permeability of the blood-
brain-barrier (BBB) [1]. Features of SVD probably develop over
many years before becoming clinically evident, hence SVD can
cause several different types of distinct or overlapping clinical
presentations such as progressive cognitive decline or vascu-
lar dementia (VaD), physical disabilities e.g. vascular parkin-
sonism (VaP), but also it often results in sudden onset lacunar
stroke (LS) [2]. Recently the number of lesions attributable to
SVD has expanded. The main imaging features of SVD are now
recognized all to be inter-related and visible on conventional
magnetic resonance imaging (MRI). They include acute LIs or
hemorrhages, lacunes (which reﬂect old infarcts), WMLs,
visible perivascular spaces (PVS), microbleeds (MCBs), and
brain atrophy [2]. Lacunes and WMLs are the hallmarks of SVD,
they often coexist, but in some patients one type of imaging
appearance may predominate. Whether they share similar or
different pathogenesis and risk factors is a matter of debate.
Population-based studies revealed that age-related WMLs are
present in MRI in over 95% of elderly individuals aged between
60 and 90 years [3]. The Leukoaraiosis and Disability Study
(LADIS) found WMLs progression in 74% of participants over 3
years particularly in those with conﬂuent lesions at baseline
[4]. Progression of SVD is associated with risk of stroke,
cognitive decline, gait abnormalities and disability, and
therefore it is important to identify associated factors
especially those that could be treatable. The relationships of
traditional risk factors with SVD are still not completely
understood and atherothrombotic risk factors are not consis-
tently common in patients with different SVD manifestations.
In a systematic review of 16 studies comparing risk factors
between patients with different stroke etiology, hypertension
and diabetes were more frequent in patients with LS than in
large vessel strokes [5]. Most community-based studies
consistently showed that age, hypertension and smoking
were associated with WMLs, however they failed to ﬁnd an
association with diabetes [6]. The majority of studies demon-
strated that older age and hypertension predicted WMLs
progression, however studies on association between diabe-
tes, cholesterol levels or statin use gave conﬂicting results [4,7].
Although the clinical and radiological course of SVD was
evaluated in many studies especially focusing on patients with
LS or asymptomatic SVD patients, the prognosis of SVD and
predictors of radiological progression, especially in chronic
SVD manifestations e.g. VaP or VaD are not well known and
have been rarely studied [8]. Variability in clinical and
radiological presentations of SVD may be attributable to
burden of traditional vascular risk factors leading to endothe-
lial dysfunction, but also may be due to other hemodynamic
or hemostatic factors, however their signiﬁcance in the
pathogenesis and prognosis of SVD is not clear. Given the
spectrum of SVD pathological pathways – from BBB dysfunc-
tion to atherosclerosis it is likely that several components ofﬁbrinolytic or inﬂammatory-atherothrombotic cascade are
involved. Studies investigating association between different
biochemical compounds e.g. serum lipid fractions and
hemostatic markers and risk of LS or SVD radiological burden
gave conﬂicting results [9]. Previous studies have suggested
that the blood viscosity measured in LS was higher than in
other stroke subtypes and that increasing triglycerides
concentration and decreased LDL cholesterol were associated
with WMLs in elderly population [10,11]. However, little is
known if they can predict further radiological progression in
SVD and add predictive capacity beyond vascular risk factors.
We hypothesized that speciﬁc markers involved in ﬁbrinolytic
process and lipid metabolism are linked to risk of SVD
radiological progression and examined if they are related to
different SVD clinical manifestations: LS, VaD or VaP.
2. Materials and methods
A single-center, prospective cohort study, with 2 years of
radiological follow-up was performed as a part of SHEF-CSVD
Study (Signiﬁcance of HEmodynamic and hemostatic Factors
in the course of different manifestations of Cerebral Small
Vessel Disease) [12]. The study group consisted of 132 patients
(54 with LS, 50 with VaD, 28 with VaP) considered to be caused
by sporadic SVD of whom 7 patients died and 2 withdrawn a
consent during follow-up. Finally 123 patients were analyzed:
49 with LS (39.8%), 48 with VaD (39%) and 26 with VaP (21.1%)
(Fig. 1). Baseline demographic data, clinical and radiological
characteristics of patients who were excluded from ﬁnal
analysis were comparable to those of the included patients.
The patients were recruited from Neurological Outpatient
Department and prospectively enrolled to the study between
December 2011 and June 2014. The MRI examination was
performed at baseline and repeated at the end of the 2-year
follow-up with the aim of assessing possible progression of
WMLs and development of new lacunes or other lesions. Given
the nature of this study, the aim of research is hypothesis-
generating rather than conﬁrmatory. The study protocol and
methods have been thoroughly described elsewhere [12].
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a ﬁrst ever recent LS or newly diagnosed VaD and VaP
presumed to be caused by sporadic SVD. Although SVD
remains a heterogeneous disease, the majority of SVD
especially in elderly is sporadic and the core mechanism
underlying brain injury is assumed to be ischemia acting
through arteriolar narrowing or failure of cerebral autoregu-
lation. However, LS may occasionally be caused by other
etiologies (e.g. artery-to-artery or cardiac embolism), and
similarly, WMLs may be seen with other vascular or
nonvascular conditions (e.g. due to CADASIL, vasculitis,
amyloid angiopathy, multiple sclerosis, sarcoidosis or Lyme
disease). Every effort was taken to perform the differential
diagnosis to include patients with sporadic SVD only. The
patients were diagnosed based on the complex evaluation of
past medical history, clinical context, available diagnostic
tests (e.g. carotid and transcranial duplex ultrasound, holter
ECG) and according to typical radiological and clinical picture:
LS – according to the OCSP Criteria; VaD and VaP after
exclusion of other neurodegenerative conditions with the use
of clinical tools easily applied in clinical practice: Hurtig
criteria or NINDS-AIREN criteria with Modiﬁed Hachinski
Ischemic Scale ≥ 7 points, respectively [13–15]. Patients with
non-SVD related WMLs, signiﬁcant stenosis (≥50%) of a major
extracranial or intracranial artery, atrial ﬁbrillation, life
expectancy of less than 6 months, and MRI contraindications
were excluded. Participants were aged between 60 and 90
years, they were independent (total Barthel Index ≥ 80 points)
and had no severe dementia (MMSE ≥ 12 points). Those with
recurrent LS or strategic single-infarct dementia or with post-
stroke VaD or VaP were not included. Mean time from ﬁrst
symptoms to enrollment was 23.2  10 months in VaD and 25
 10 months in VaP ( p = 0.5). To prevent confounding
by hyperacute phase responses, all LS patients underwent
study procedures at least 2 weeks (mean 17.5  3.8 days)
after their index strokes. The study complied with the
Declaration of Helsinki. All participants signed an informed
consent form. The study was approved by the local Medical
Ethics Committee (46/WIM/2010).
2.1. Procedure
2.1.1. Laboratory examinations
We investigated a set of 9 markers of hemostasis (tissue
factor [TF], thrombomodulin [TM], beta-thromboglobulin
[BTG], ﬁbrinogen, D-dimer) and lipid metabolism (serum
total cholesterol [TC], high density lipoprotein cholesterol
[HDL-C], low-density lipoprotein cholesterol [LDL-C], triglyc-
erides [TG]). Fasting morning samples were collected at
baseline into an EDTA containing tube, centrifuged and
fractionated at 3000  g for 15 min at 4 8C and stored at
80 8C. Tissue factor, TM, BTG measurements were per-
formed using commercially available ELISA kits according
to manufacturer protocol (Bio-Source, Europe, Nivelles,
Belgium). For each sample, duplicate readings were per-
formed, intra-assay coefﬁcients of variation was <10%. Other
biochemical markers were measured by automatic biochem-
ical analyzer. In order to improve the wording in manuscript,
whenever a compound or metabolite is mentioned, we
actually mean its serum or plasma concentration.2.1.2. MRI evaluation
MRI examinations were performed at baseline and after 2
years (mean 22.7  3.7 months; LS 22.6  3.8; VaP 21.7  4.3;
VaD 23.2  3.3 months, ANOVA p = 0.28). For MRI evaluation
we used imaging with standard T2-weighted, FLAIR and
gradient echo sequences. All MRI scans were obtained using
the same scanner (GE Healthcare 1.5 T scanner). Baseline and
follow-up scans were read independently by the same
experienced investigator (E.S.) blinded to the clinical diagnosis
and used to calculate change scores over time. We categorized
MRI ﬁndings according to STRIVE (Standards for Reporting
Vascular Changes on Neuroimaging) guidelines as a reference
standard [16]. As imaging features of SVD can be quantiﬁed
they were used as markers of the presence and severity of SVD
in the study. Images were rated for the presence of lacunes,
WMLs, MCBs, and PVS according to a recommended visual SVD
scale which provides a more complete overall view of the
impact of SVD on the brain than do the individual MRI features
separately [17].
White matter lesions. Periventricular (pWMLs) and deep
WMLs (dWMLs) were visualized on T2 and PD/FLAIR images as
ill-deﬁned hyperintensities ≥5 mm. The simple modiﬁed
Fazekas rating scale was used to estimate the extent of the
pWMLs and dWMLs as this scale demonstrated good inter-
rater agreement and correlated sufﬁciently with the volume of
white matter damage derived from fully quantitative mea-
surements [18–20]. Mild WMLs (grade 1) was deﬁned as
punctate lesions in the deep white matter with a maximum
diameter of 9 mm for a single lesion and of 20 mm for grouped
lesions. Moderate WMLs (grade 2) were early conﬂuent lesions
of 10–20 mm single lesions and >20 mm grouped lesions in
any diameter, and no more than connecting bridges between
the individual lesions. Severe WMLs (grade 3) were single
lesions or conﬂuent areas of hyperintensity of ≥20 mm in any
diameter. All studied patients had at least Fazekas grade 1
WMLs. One point in SVD scale was awarded if (early) conﬂuent
deep WMLs (Fazekas score 2 and 3) or irregular periventri-
cular hyperintensities extending into the deep white matter
(Fazekas score 3) were present.
Lacunes. One point on the SVD scale was awarded when 1 or
more lacunes (small <15 mm, subcortical lesions of similar
signal to CSF, i.e., increased signal on T2-weighted, decreased
signal on FLAIR and T1-weighted images) were present.
Cerebral microbleeds. Cerebral microbleeds were deﬁned as
small (<5 mm), homogeneous, round foci of low signal
intensity on T2*-weighted images in basal ganglia, thalamus,
white matter, or cortico-subcortical junction. The presence of 1
or more microbleeds gave 1 point on the SVD scale.
Enlarged perivascular spaces. We deﬁned PVS as small
(<3 mm) punctate (if perpendicular) and linear (if longitudinal
to the plane of scan) hyperintensities on T2 images. One point
was awarded if moderate to extensive (10–25 or >25) enlarged
perivascular spaces were present [21].
Finally the presence of each of the above markers was
awarded with 1 point, producing a minimum score of 0 and a
maximum of 4, representing the total MRI load of SVD.
The complete set of baseline MRI variables of interest,
included qualitative assessment of brain LIs, WMLs, MCBs, and
cortical atrophy, was compared with those obtained from
follow-up MRI scans.
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rating of SVD radiological progression expressed by WMLs
progression or development of new lacunes was performed.
WMLs progression and lacunes were rated on FLAIR images as
proposed by Prins et al., in which absence or presence of
progression (0 and 1, respectively) was rated in 3 periven-
tricular regions (frontal caps, occipital caps, bands), 4
subcortical white matter regions (frontal, parietal, occipital,
temporal), basal ganglia, and infratentorial region [22]. We
deﬁned radiological SVD progression as an increase of WMLs
(WMLs progression group) or new lacunes (new lacunes group)
in one or more periventricular and/or subcortical regions.
2.1.3. Atherothrombotic risk evaluation
Based on medical records, physical examination and compre-
hensive history available at baseline, we evaluated athero-
thrombotic risk factors, including tobacco use, diabetes,
hyperlipidemia, hypertension, coronary artery disease (CAD)
and peripheral vascular disease (PAD). Hypertension was
deﬁned as systolic BP (SBP) ≥ 140 mm Hg and/or diastolic
BP ≥ 90 mm Hg, or use of antihypertensive medication.
Diabetes mellitus was deﬁned as fasting serum glucose
concentration ≥ 126 mg/dl, hemoglobin A1c ≥ 6.5%, or use of
antidiabetic medication. The following criteria were used to
diagnose polymetabolic syndrome: waist circumferen-
ce ≥ 102 cm in men or ≥88 cm in women; HDL < 40 mg/dl in
men and <50 mg/dl in women or on drug treatment; elevated
blood pressure ≥ 130 mmHg systolic or ≥85 mmHg diastolic or
on drug treatment; elevated TG ≥ 150 mg/dl or on drug
treatment; and elevated fasting glucose (FG) ≥ 100 mg/dl or
on treatment for diabetes. Coronary artery disease (CAD) was
deﬁned in patients with stable angina, prior myocardial
infarctions (MIs), prior percutaneous revascularization, coro-
nary artery bypass graft, angiographically proven coronary
atherosclerosis, or reliable non-invasive evidence of myocar-
dial ischemia. Previous history of CAD and peripheral artery
disease (PAD) was recorded based on clinical history and
documented investigations. Patients who were smokers at the
time of analysis were classiﬁed as current smokers. To
determine baseline blood pressure control we performed
24 h ABPM using a portable non-invasive oscillometric and
auscultatory device (Schiller MT-300). All patients received
optimal medical treatment, according to guidelines. As we
reported previously, there were no signiﬁcant differences with
regard to mean age and distribution of other vascular risk
factors between patients with VaD and VaP [23].
2.2. Statistical analysis
Log-normal data were compared using paired t-tests, non-
normal data were analyzed using nonparametric tests, the chi-
square test was used for comparisons of categorical variables.
All markers were studied as continuous variables. The
difference between baseline risk factors and concentration
of biochemical compounds was compared between patients
without and with any radiological progression, with WMLs
progression or new lacunar lesions only, and between patients
with LS, VaD and VaP. All variables that achieved a p-value ≤0.1
in any of the analysis were included in the multivariate
regression model as candidate variables and then removed bybackward stepwise selection procedure. Backward elimination
of nonsigniﬁcant variables ( p > 0.1) was subsequently used to
generate a minimal model. We assessed the relationship
between analyzed factors at baseline (independent factors)
and SVD progression at 2-years follow-up (dependent factor).
The results are presented as the odds ratio (OR) with 95%
conﬁdence intervals (CI). We performed three separate
analyses: (1) any progression of WMLs and/or development
of new lacunes, (2) development of new lacunes, (3) WMLs
progression. To evaluate a variable's power to predict SVD
progression, we also used receiver operating characteristic
(ROC). Due to the small sample size threshold-, sensitivity and
speciﬁcity values were not reported. Statistical signiﬁcance
was set at p-value <0.05 in all analyses. All data are presented
as mean  SD values. All analyses were performed using
Statistica 12 software (StatSoft Inc, USA).
3. Results
3.1. Patient characteristics
Above one-third of patients (34.9%) experienced radiological
progression during the study ﬂow. Isolated WMLs progression
was the most common ﬁnding and was discovered in 43%
(n = 18) of these cases, new lacunes in 23.2% (n = 10), both
WMLs progression and new lacunes in 15 patients (34.8%).
Mean age, sex distribution, prevalence of major vascular risk
factors did not signiﬁcantly differ between patients with and
without radiological progression, however more than half of
patients who experienced progression had VaD (Table 1).
Baseline total SVD load on MRI assessed in SVD scale and
Fazekas scale were similar in patients without and with
radiological progression, however those who progressed had
higher load of deep WMLs (Table 2). Also the prevalence of
lacunes, CMBs, PVS and brain atrophy at baseline did not differ
signiﬁcantly between groups.
3.2. Biochemical markers
There were signiﬁcant differences between patients with and
without radiological progression with regard to concentration
of ﬁbrinolysis markers and lipid metabolites: patients who had
progressed had signiﬁcantly elevated ﬁbrinogen, D-dimer, TF
and lower TC (Table 3). There were also some differences in
biochemical proﬁle between patients with diverse markers of
radiological progression. Compared with patients without
progression, those with new lacunes had signiﬁcantly lower
HDL and higher TF while patients with new WMLs had lower
eGFR and tended to have higher BTG.
Fibrinogen and HDL were the only markers signiﬁcantly
associated with risk of any radiological progression in
multivariable analysis. Moreover, TF and BTG were marginally
associated with risk of new lacunes and new WMLs,
respectively (Table 4). Additional analyses after adjustment
for age and sex or baseline Fazekas score did not change these
results essentially. We also made a comparison between
patients with different clinical manifestations of SVD who
experienced radiological progression. Fibrinogen was signiﬁ-
cantly elevated in all SVD groups. Patients with VaD who
Table 1 – Baseline characteristics of studied patients without and with radiological progression.
Variables No progression Radiological progression p
n 80 43 –
SVD manifestation; N (%)
LS 37 (46.3) 12 (27.9) 0.09
VaD 26 (32.5) 22 (51.2)
VaP 17 (21.3) 9 (20.9)
Age. mean (SD) years 71.25 (8.07) 73.8 (8) 0.1
Age/decades
<65 yrs 34 (42.5) 14 (32.6) 0.47
65–75 yrs 30 (37.5) 17 (39.5)
>75 yrs 16 (20) 12 (27.9)
Female sex 41 (51.3) 19 (44.2) 0.57
Hypertension 69 (86.3) 37 (86) 0.99
24h MAP 93.11 (11.7) 97.3 (12) 0.15
Mean 24 h SBP 132.4 (16.9) 135.2 (16.7) 0.4
Mean 24 h DBP 73.4 (11) 78.4 (11) 0.11
CAD 18 (22.5) 6 (14) 0.34
Diabetes mellitus 46 (56.3) 23 (53.5) 0.85
Current smoking 25 (31.3) 12 (27.9) 0.83
Hyperlipidemia 62 (77.5) 29 (67.4) 0.28
PAD 5 (6.3) 5 (11.6) 0.31
PS 37 (46.3) 16 (37.2) 0.34
Obesity (BMI ≥ 30 kg/m2) 63 (78.8) 29 (67.4) 0.19
CKD 9 (11.3) 9 (20.9) 0.18
Use of statin medications 64 (80) 32 (74.4) 0.49
Use of antihypertensive therapy 67 (83) 35 (81) 0.81
Daily use of aspirin 68 (85) 32 (74.4) 0.22
Values are means (SD) or numbers of patients (%).
Continuous variables were compared using the Mann–Whitney U test. The Chi-square test was used for frequency comparisons.
SVD, small vessel disease; VaD, vascular dementia; VaP, vascular parkinsonism; LS, lacunar stroke; BMI, body mass index; CKD, chronic kidney
disease; CAD, coronary artery disease; MAP, mean arterial pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; PAD, peripheral
vascular disease; PS, polymetabolic syndrome.
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TC and HDL while subjects with VaP tended to have low TG
(Table 5).
In the multivariate analysis performed with regard to
clinical manifestation of SVD, ﬁbrinogen was associated with
risk of any radiological progression in all groups: LS (OR 1.01;
95% CI (1.002–1.02), p = 0.02), VaD (OR 1.007; (0.99–1.01), p = 0.07)
and VaP (1.002; (1–1.012), p = 0.04). Moreover, HDL (OR 0.97;
(0.93–1.001), p = 0.05) and TC (OR 0.98; (0.96–1.001), p = 0.07)
were also marginally associated with this risk in VaD and TG in
VaP (OR 0.98; (0.95–1.002), p = 0.08). Area under the ROC curve
was comparably large for ﬁbrinogen [AUC 0.65 (0.54–0.76),
p < 0.01] and exceeded baseline HDL [AUC 0.55 (0.44–0.65),
p = 0.3] (Fig. 2).
4. Discussion
Our study demonstrated on a large group of initially
independently living elderly, stratiﬁed for 3 different SVD
manifestations, that both WMLs and lacunes progressed over
time within 2 years of observation. We found that higher
concentrations of ﬁbrinogen were associated with an in-
creased risk of radiological progression expressed by new
lacunes or WMLs, and our results support the hypothesis that
coagulation pathway contributes to the pathogenesis of SVD.
This association was independent of age, sex, baseline SVD
load and type of SVD manifestations regardless they weresubacute (LS) or chronic (VaD or VaP). Interestingly, there were
some differences between other associations with the main
radiological determinants of SVD. Lower HDL and increased TF
predicted development of new lacunes but not WMLs
progression while higher BTG was associated with risk of
WMLs progression. That difference supports the concept of
multiple different mechanisms involved in the pathogenesis
and progression of SVD. Lacunar strokes are thought to
represent the focal manifestation of actually a diffuse
abnormality of the small cerebral arterioles resulting in a
state of chronic hypoperfusion of the brain white matter,
eventually resulting in degeneration of myelinated ﬁbers as a
consequence of repeated selective oligodendrocyte death.
Multiple infarcts or WMLs rather denote a more generalized
phenomenon such as inﬂammation, oxidative stress with
disruption in the BBB [24].
The study demonstrated that among a panel of different
biochemical markers, ﬁbrinogen was the only one that was
signiﬁcantly related to radiological progression in patients
with LS, VaD or VaP. These ﬁndings suggest haemostatic
activation may be an important cause or contributor to
progression of SVD. Fibrinogen is an inﬂammatory marker,
and a marker of systemic hypercoagulability acting as an
important factor in the coagulation cascade. It has important
hemostatic properties as it induces red cell aggregation and
affects platelet aggregation and endothelial function. It is also
assumed to be a faithful marker of BBB dysfunction. High
levels serve as nonspeciﬁc marker for inﬂammatory disease,
Table 2 – Baseline MRI features of studied patients with and without further radiological progression.
Baseline MRI variables No progression Radiological progression p
N 80 43 –
SVD score
0 2 (2.5) 0 0.40
1 23 (28.8) 12 (27.9)
2 22 (27.5) 18 (41.9)
3 20 (25) 9 (20.9)
4 13 (16.3) 4 (9.3)
Fazekas Scale
1 17 (21.3) 3 (7) 0.12
2 43 (53.8) 28 (65.1)
3 20 (25) 12 (27.9)
Fazekas Score (mean) 2 (0.76) 2.23 (0.53) 0.09
pWMLs 1.53 (0.98) 1.62 (0.85) 0.71
dWMLS 1.47 (0.87) 2.04 (0.87) <0.01
Lacunes 42 (52.5) 18 (41.9) 0.34
Microbleeds 14 (17.5) 5 (11.6) 0.44
PVS 34 (42.5) 19 (44.2) 0.99
Atrophy 20 (25.3) 13 (30.2) 0.67
Values are means (SD) or numbers of patients (%).
SVD, small vessel disease; WMLs, white matter lesions; pWMLs, periventricular WMLs; dWMLs, deep WMLs; PVS, enlarged perivascular spaces.
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enhance atherogenesis and lead to increased risk of cerebro-
vascular diseases. In the ASPS study, higher serum ﬁbrinogen
levels were independently associated with WMLs and lacunar
lesions on MRI [25]. In patients with symptomatic SVD,
ﬁbrinogen has been correlated with the amount of leukoar-
aiosis in patients with lacunar strokes and VaD [26]. Also in a
systematic review and meta-analysis, concentrations of
ﬁbrinogen and D-dimer were higher in chronic lacunar stroke
versus non-stroke patients [27]. On the opposite Aribisala et al.
found no association between inﬂammatory biomarkers,
ﬁbrinogen and WMLs among 634 community-dwelling older
people [28]. We found increased concentrations of BTG
especially in patients with WMLs progression what may
represent ongoing platelet activation, which is in line with
recent study of Yokote et al., who demonstrated elevated
release of BTG in patients with atheromatous plaques at brain
penetrating arteries [29]. Elevated BTG and other markers of
endothelial dysfunction (intercellular adhesion molecule-1 or
tissue factor pathway inhibitor) were elevated independent of
conventional risk factors in patients with LS and leukoaraiosis
[30]. On the other hand patients with new lacunes had
increased TF in our study, what may rather reﬂect prothrom-
botic changes as TF acts as a trigger for the extrinsic
coagulation pathway.
Interestingly, in this study, the concentrations of serum
HDL and TC on admission in patients who experienced
radiological progression were both lower than those in non-
progressive group and these markers tended to be associated
with WMLs or lacunes progression in VaD patients. That
ﬁnding was in line with the LADIS study results which
documented that among 639 elderly subjects with some
degree of WMLs on MRI, low HDL was associated with incident
lacunes in VaD subgroup [31]. Other investigators found that
mid-life lower HDL concentration was associated with late-life
WMLs [32]. The ASPS study also revealed that lower TC was
associated with WMLs [33]. In a population based cohortsincreasing triglycerides and decreasing LDL were associated
with frequency and severity of all MRI markers of SVD in older
community persons [11]. However, ﬁndings on the association
between cholesterol fractions levels and SVD are not consis-
tent. LDL, total cholesterol and triglicerydes were not
independent risk factors for any SVD subgroups in LADIS
and in the cross-sectional ARIC study of 1827 community-
dwelling participants, incident lacunes related to lipohyali-
nosis were associated with LDL but not TC [34]. Also in a
Rotterdam Scan Study progression of SVD was related to
vascular risk factors (age, female sex, smoking, hypertension),
baseline lesion load but not TC and HDL [35]. On the opposite,
another recent study documented that lower TC and HDL
levels were associated with the presence of another SVD
radiological marker – deep CMBs [36].
The relationship between plasma or imaging markers and
radiological progression of SVD is not clear. Although SVD is
considered to result from cerebral arteriolar occlusive disease,
the pathogenesis is largely unknown and probably the exact
mechanisms of SVD radiological and clinical manifestations
differ [37]. Classical cardiovascular risk factors are not
consistently common in patients with SVD and pathophysiol-
ogy of SVD may be independent from that of atherosclerotic
large artery disease and other, nonvascular contributing
mechanisms play a role in the cause of SVD [38]. Probably
the inﬂuence of systemic factors on the endothelium results in
increase in permeability of the BBB what initiates pathologic
changes. In majority of the studies, the causal relationship
between biochemical markers cannot be determined because
majority of them had cross-sectional design. We cannot
directly compare our results with others because studies on
SVD radiological progression usually concentrated on inﬂam-
matory biomarkers and did not focus on hemostatic factors. It
is of interest that, we observed some difference in biochemical
proﬁles between LS, VaD and VaP. Although this observation
requires replication to ensure validity, if validated, it lends
support to the involvement of different pathways in the
Table 3 – Comparison of biochemical markers of studied patients without and with any radiological progression, with new
lacunes or with WMLs progression.
Variables New lacunes or WMLs progression New lacunes WMLs progression
No Yes p* Yes p* Yes p*
N 80 43 – 25 – 33 –
Age (years) 71.25 (8.07) 73.8 (8) 0.1 72.90 (8.8) 0.55 72.78 (7) 0.46
MPV (ﬂ) 9.22 (1.1) 9.27 (2) 0.84 9.1 (1.2) 0.75 9.10 (2.69) 0.78
hsCRP (mg/dl) 0.68 (1.9) 0.85 (1.2 0.6 0.67 (1.01) 0.98 0.51 (0.9) 0.72
PGL (mg/dl) 121.8 (43.5) 123.53 (49.8) 0.84 135.7 (70) 0.38 113.61 (38) 0.46
HBA1c (%) 6.398 (1.1) 6.270 (0.92) 0.53 6.26 (0.76) 0.75 6.34 (1.1) 0.85
eGFR (ml/min/1.73 m2) 81.17 (23.1) 72.45 (26) 0.06 66.2 (35.1) 0.07 68.03 (21.3) 0.03
LDL-C (mg/dl) 112.29 (39.4) 102.8 (33.6) 0.18 110.3 (37.6) 0.88 102.52 (30.7) 0.33
HDL-C (mg/dl) 51.43 (15) 45.8 (14.9) 0.05 39.1 (16.5) 0.01 47.73 (14.4) 0.35
TG (mg/dl) 138.06 (90.7) 112.36 (54.7) 0.09 114.3 (41.7) 0.42 122.87 (70.4) 0.51
TC (mg/dl) 189.46 (48) 171.2 (34.2) 0.03 174.8 (25.6) 0.35 172.03 (31.4) 0.15
D-dimer (mg/ml) 0.72 (0.6) 1.14 (1.2) 0.03 0.86 (0.7) 0.59 0.86 (1.04) 0.50
Fibrinogen (mg/dl) 329.74 (85) 382.33 (87.2) 0.003 384.56 (116.6) 0.08 382.75 (92.8) 0.03
BTG (ng/ml) 25.27 (43.1) 47.09 (92.4) 0.13 45.79 (7.1) 0.28 55.06 (90.08) 0.06
sTM (ng/ml) 5.7 (4.4) 5.4 (1.7) 0.92 6.0 (2.7) 0.82 5.9 (2.1) 0.85
TF (pg/ml) 49.77 (15.4) 61.9 (22.1) 0.04 80.84 (17.6) 0.003 38.7 (14.8) 0.33
Values are means (SD).
* Compared with patients with no radiological progression.
WMLs, white matter lesions; sTM, soluble thrombomodulin; TF, tissue factor; MPV, mean platelet volume; PGL, plasma glucose level; BTG, beta
thromboglobulin; TF, tissue factor.
Table 4 – Multivariate analysis of independent variables
associated with SVD progression.
Variables New lacunes or WMLs progression p
Fibrinogen 1.02 (1.006–1.011) 0.01
HDL 0.97 (0.94–1.005) 0.04
TC 0.99 (0.97–1.001) 0.09
Variables New lacunes p
Fibrinogen 1.02 (1.003–1.05) 0.02
HDL 0.96 (0.93–1.0) 0.05
TF 1.07 (0.99–1.1) 0.07
Variables WMLs progression p
Fibrinogen 1.007 (1.001–1.01) 0.01
BTG 1.005 (0.99–1.01) 0.07
Values are OR (95% CI); WMLs, white matter lesions.
TF, tissue factor; BTG, beta thromboglobulin; TC, total cholesterol;
HDL, high density lipoprotein.
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radiological course of VaP and VaD caused by SVD, which
makes our data the more important. The present study
documented that patients with LS and VaP had similar risk
for radiological progression, however patients with VaD
tended to have this risk higher. Majority of our patients with
SVD had moderate or severe WMLs on baseline. Several
longitudinal studies have investigated the rate and predictors
for progression of WMLs, and the most consistent predictor for
progression of WMLs is the baseline severity of WMLs. Patients
with punctuate WMLs usually have minimal progression of
WMLs, whereas those with early conﬂuent and conﬂuent
WMLs at baseline have rapid progression of WMLs. While
many studies report an association between atrophy and SVD
it is not speciﬁc to SVD and it may occur in normal aging.We acknowledge that there are several limitations of this
study. The major weakness is the small number of patients
from a single center with data-driven approaches to selecting
variables what might have produced biased estimates and the
results may not be generalizable to other population. The
number of patients in each group was small which decreased
the power of our study in detecting some signiﬁcant
differences among different groups. However, this is also a
limiting factor in most published reports on the subject.
Second, because of its single-center observational nature,
selection and severity bias may be reﬂected in the character-
istics of our study population. It is also possible that certain
unobserved factors such as genetic background and patho-
physiology of SVD may also inﬂuence the likelihood of SVD
progression after controlling most associated risk factors. The
study is therefore regarded as hypothesis generating rather
than deﬁnitive, and a larger study and replication are needed
for more robust conclusions. Although patients with VaP and
VaD were included to the present study immediately after
diagnosis but they were in an advanced stage of their disease,
therefore it remains unknown whether our results can be
applied to less severely affected patients. Measuring progres-
sion of WMLs burden is yet a further challenge and the major
weakness was a visual assessment of the imaging. However,
Fazekas scale remains the most widely used system for
describing white matter disease severity in publications and it
is histopathologically related with SVD [39]. Fully quantitative
techniques also suffer from several pitfalls, including changes
in signal intensity of the WMLs or aging brain [40]. These
problems usually aggravates in a multicenter setting with the
use of different MRI scanners which cannot provide complete-
ly identical image sequences. The overall study period in our
study (24 months) could ideally have been longer to reach
more signiﬁcant results. Therefore, future studies are needed
to develop a predictive risk score for chronic manifestations of
Table 5 – Comparison of baseline biochemical markers of studied patients with lacunar stroke, vascular dementia and
parkinsonism without and with any radiological progression.
Variables Lacunar stroke VaD VaP
No progression Progression p No progression Progression p No progression Progression p
N 36 13 – 27 21 – 17 9 –
Age (years) 69.72 (9.3) 69.46 (7) 0.93 72.93 (6.9) 75.86 (9) 0.21 71.82 (6.5) 75.33 (4) 0.16
Hypertension 33 (91.7) 13 (100) 0.55 24 (88.9) 18 (85.7) 0.9 12 (70.6) 6 (66.7) 0.9
CAD 9 (25) 1 (7.7) 0.25 8 (29.6) 4 (19) 0.51 1 (5.9) 1 (11.1) 0.9
Diabetes mellitus 21 (58.3) 7 (53.6) 0.9 15 (55.6) 12 (57.1) 0.9 9 (52.9) 4 (44.4) 0.9
Current smoking 12 (33.3) 4 (30.8) 0.9 6 (22.2) 4 (19) 0.9 7 (41.2) 4 (44.4) 0.9
Hyperlipidemia 27 (75) 10 (76.9) 0.9 23 (85.2) 13 (61.9) 0.09 13 (76.5) 5 (55.6) 0.38
PAD 1 (2.8) 0 0.9 2 (7.4) 2 (9.5) 0.9 2 (11.8) 3 (33.3) 0.3
PS 18 (50) 6 (46.2) 0.9 13 (48.1) 8 (38.1) 0.56 6 (35.3) 2 (22.2) 0.66
Obesity (BMI ≥ 30 kg/m2) 9 (25) 7 (53.8) 0.08 6 (22.2) 5 (23.8) 0.9 2 (11.8) 2 (22.2) 0.59
CKD 4 (11.1) 5 (38.5) 0.04 2 (7.4) 3 (14.3) 0.64 2 (11.8) 2 (22.2) 0.59
Use of statin medications 33 (91.7) 12 (92.3) 0.99 22 (81.5) 13 (61.9) 0.19 9 (52.9) 7 (77.8) 0.39
Antihypertensive therapy 33 (91.7) 11 (84) 0.72 22 (81) 18 (85.7) 0.75 12 (70.6) 6 (66.7) 0.9
Daily use of aspirin 35 (97.2) 13 (100) 0.99 21 (77.8) 14 (66.7) 0.51 12 (70.6) 5 (55.6) 0.66
hsCRP (mg/dl) 0.88 (2.7) 0.50 (0.8) 0.63 0.40 (0.6) 1.04 (1.4) 0.05 0.69 (0.9) 0.95 (1.2) 0.57
D-dimer (mg/ml) 0.7 (0.8) 0.60 (0.2) 0.48 0.64 (0.5) 1.42 (1.4) 0.04 0.68 (0.4) 1.33 (1.5) 0.19
Fibrinogen (mg/dl) 331.4 (72) 385 (71.1) 0.04 325.9 (92.2) 389.0 (92.3) 0.04 331.0 (105.8) 361.8(101.3) 0.04
MPV (ﬂ) 9.1 (1.1) 9.28 (1.7) 0.83 9.0 (1) 8.94 (2.2) 0.91 9.56 (0.88) 10.06 (1.7) 0.35
LDL-C (mg/dl) 109.6 (42.1) 94.6 (31.5) 0.25 117.4 (37.7) 105.9 (35.4) 0.30 110.2 (37.3) 107.3 (33.8) 0.85
HDL (mg/dl) 47.4 (10.3) 44.3 (9.1) 0.35 53.75 (20.5) 43.57 (16.5) 0.08 56.51 (12.3) 53.13 (16.7) 0.57
TG (mg/dl) 150 (118) 131.6 (76.4) 0.61 116.96 (51.8) 106.6 (41.9) 0.47 142.8 (58.4) 97.9 (40.8) 0.05
TC (mg/dl) 179.5 (47.4) 163.7 (28.8) 0.27 199.42 (50.1) 173 (33.5) 0.05 196.2 (44.2) 177.9 (43.9) 0.33
PGL (mg/dl) 126.8 (46.9) 148.6 (66) 0.21 115 (42.1) 117.5 (42.6) 0.84 121.38 (38.6) 101.3 (17.1) 0.16
eGFR (ml/min/1.73 m2) 81.13 (29.1) 74.1 (26.5) 0.45 84.74 (15.7) 74.9 (26.2) 0.14 76.13 (15.6) 64.28 (26.4) 0.17
BTG (ng/ml) 21.2 (36.3) 59.5 (102) 0.14 23.33 (35) 54.79 (102.2) 0.19 34.04 (62) 5.03 (7.9) 0.28
sTM (ng/ml) 6.2 (6.5) 6.5 (2.2) 0.90 5.2 (1.1) 5.4 (2.0) 0.74 5.3 (5.9) 5.7 (2.0) 0.47
TF (pg/ml) 49.88 (11) 66.2 (21.6) 0.40 53.72 (23.3) 62.5 (23.9) 0.44 38.59 (14.8) 58.88 (9.6) 0.19
Values are means (SD) or numbers of patients (%).
VaD, vascular dementia; VaP, vascular parkinsonism; LS, lacunar stroke; sTM, soluble thrombomodulin; TF, tissue factor; MPV, mean platelet
volume; PGL, plasma glucose level; BTG, beta thromboglobulin; TF, tissue factor; CAD, coronary artery disease; PAD, peripheral vascular
disease; PS, polymetabolic syndrome.
Fig. 2 – ROC curves for baseline fibrinogen and HDL.
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vascular processes in their development. On the other hand
our study has some advantages. We included a well-phenotyped group of patients with SVD including rarely
studied chronic VaP and VaD subjects using uniform diagnos-
tic procedures. Second, our study had 24-months of follow-up
with repeated MRI examinations, what allowed us to assess
the long-term effects of different baseline measures on
radiological progression.
4.1. Summary
In conclusion, our results support that hemostatic factors and
lipid metabolism play a role in SVD radiological progression.
Fibrinogen concentration was independently associated with
an increased risk of radiological progression expressed by new
lacunes or WMLs progression regardless of the clinical SVD
manifestation. In addition, the two radiological subtypes of
SVD demonstrated differences in other associated biochemi-
cal markers. Lower HDL and increased TF predicted develop-
ment of new lacunes, and higher BTG was associated with risk
of WMLs progression. Further research is required to ensure
the validity of our ﬁndings.
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